Angina News and Research RSS Feed - Angina News and Research

Angina is chest pain or discomfort that occurs when an area of your heart muscle doesn't get enough oxygen-rich blood. Angina may feel like pressure or squeezing in your chest. The pain also may occur in your shoulders, arms, neck, jaw, or back. It can feel like indigestion.
Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Pre-procedural use of antiplatelet therapy becoming less routine in heart attack treatment

Doctors worried about dangerous blood clots in patients undergoing a coronary artery procedure— such as angioplasty to treat a heart attack — will often administer antiplatelet therapy to head off complications. [More]
CMR 'may be preferable' to SPECT for CHD prognosis

CMR 'may be preferable' to SPECT for CHD prognosis

Long-term follow-up of the CE-MARC study suggests that cardiovascular magnetic resonance could be a better predictor of cardiovascular events than single-photon emission computed tomography in patients with coronary heart disease. [More]
Researchers highlight need for more tailored approaches to treating chronic obstructive pulmonary disease

Researchers highlight need for more tailored approaches to treating chronic obstructive pulmonary disease

Speakers at the recent REG 2016 Summit highlighted the need for more research into the nature and effectiveness of treatment for COPD (Chronic Obstructive Pulmonary Disease) in a real-world environment. [More]
Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

Clinical study shows association between Corus CAD blood test scores and cardiovascular event rates

CardioDx, Inc., a molecular diagnostics company specializing in cardiovascular genomics, announced today results from a genomic substudy of the NHLBI-funded Prospective Multicenter Imaging Study for Evaluation of Chest Pain (PROMISE) trial in nondiabetic patients receiving the Corus CAD blood test. [More]
Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Cholesterol drug evacetrapib fails to reduce risk of cardiovascular events

Despite lowering low-density lipoprotein (LDL), known as "bad" cholesterol, while markedly increasing levels of high-density lipoprotein (HDL), or "good" cholesterol, a large clinical trial to investigate the cholesterol drug evacetrapib was discontinued early after a preliminary analysis showed it did not reduce rates of major adverse cardiovascular events, according to research presented at the American College of Cardiology's 65th Annual Scientific Session. [More]
Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

Researchers report outcomes of dipyridamole drug in treating pterygium and related dry-eye symptoms

At the Israeli Society for Vision and Eye Research conference on March 10, the MedInsight Research Institute and Center for Drug Repurposing at Ariel University presented the latest findings on positive user-reported outcomes of the repurposed drug dipyridamole in treating pterygium and related dry-eye symptoms. [More]
Aralez resubmits NDA package for YOSPRALA to FDA

Aralez resubmits NDA package for YOSPRALA to FDA

Aralez Pharmaceuticals Inc., a global specialty pharmaceutical company, today announced that it has resubmitted to the U.S. Food and Drug Administration the New Drug Application ("NDA") for its investigational candidate, YOSPRALA (PA32540/PA8140) for the secondary prevention of cardiovascular disease in patients at risk for aspirin-induced gastric ulcers. [More]
Beta-blockers could have potential benefit for COPD patients

Beta-blockers could have potential benefit for COPD patients

Beta-blockers could be used to reduce the risk of chronic obstructive pulmonary disease (COPD) exacerbations, according to new findings. [More]
Sleeping too much or too little increases risk of dying from heart disease

Sleeping too much or too little increases risk of dying from heart disease

Too much or too little sleep is linked with an increased risk of certain types of cardiovascular disease. Women and the elderly are particularly at risk.Sleeping less than four hours or more than eight hours a night increases the risk of dying from some types of coronary heart disease, such as heart attacks and unstable angina pectoris, according to a study by Norwegian and Taiwanese researchers. [More]
Working long hours may increase long-term cardiovascular disease risk

Working long hours may increase long-term cardiovascular disease risk

Working long hours—particularly 46 hours per week or more—may increase the long-term risk of cardiovascular disease (CVD) events such as heart attack, reports a study in the March Journal of Occupational and Environmental Medicine, official publication of the American College of Occupational and Environmental Medicine. [More]
African-American patients with connective tissue diseases at risk for cardiovascular disease

African-American patients with connective tissue diseases at risk for cardiovascular disease

A study based on medical records from more than a quarter million adult patients found that African-American patients with connective tissue diseases such as lupus or rheumatoid arthritis were twice as likely as white patients to suffer from narrowed or atherosclerotic blood vessels, which increase the risk of a heart attack, stroke or death. [More]
New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs

New blood clotting analysis system could help determine effects antithrombotic (anti-clotting) drugs

A new blood clotting analysis system designed in Japan makes it easier to determine the effects of taking one or more antithrombotic (anti-clotting) drugs. [More]
FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

FDA-approved, once-daily 24-hour aspirin now available for prevention of stroke and acute cardiac events

New Haven Pharmaceuticals, Inc. today announced the availability by prescription of DURLAZA, the first and only 24-hour, extended-release aspirin capsules (162.5mg) approved by the U.S. Food and Drug Administration (FDA) for the secondary prevention of stroke and acute cardiac events, including myocardial infarction (heart attack) in high-risk cardiovascular patients. [More]
Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Second-line bosutinib offers ‘durable’ response for chronic phase CML patients

Four-year results for an ongoing study of second-line bosutinib indicate that the tyrosine kinase inhibitor offers long-term efficacy with manageable side effects for patients with chronic phase chronic myeloid leukaemia. [More]
Angina in women linked with abnormal heart blood flow

Angina in women linked with abnormal heart blood flow

Chest pain in female-pattern heart disease is linked with abnormal heart blood flow, demonstrated with a drug commonly used to alleviate chest pain patients with coronary artery disease, which was found to be ineffective in patients with moderate female-pattern heart disease, but may offer some relief for sicker patients, a new Cedars-Sinai Heart Institute study shows. [More]
White coat hypertension, masked hypertension increase cardiovascular events over the years

White coat hypertension, masked hypertension increase cardiovascular events over the years

Patients whose blood pressures spikes in the doctor's office but not at home, and patients whose blood pressure spikes at home but not in the doctor's office, suffer more heart attacks, heart failure, and strokes than patients with normal blood pressures in both settings, UT Southwestern Medical Center researchers have found. [More]
New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals' DURLAZA drug delivers sustained antiplatelet control for full 24 hours

New Haven Pharmaceuticals, Inc. today announced new study data that shows the company's FDA-approved drug DURLAZA delivers sustained antiplatelet control for a full 24-hour period in high-risk patients. [More]
Upstream Medical Technologies formed to revolutionise accurate diagnosis of heart conditions

Upstream Medical Technologies formed to revolutionise accurate diagnosis of heart conditions

A new company that could revolutionise the accurate diagnosis of heart conditions was launched in Christchurch, New Zealand today. [More]
Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

Amgen gets positive CHMP opinions for Kyprolis (carfilzomib) and BLINCYTO (blinatumomab)

"We are pleased to receive positive CHMP opinions for Kyprolis and BLINCYTO as this is an important step in providing new treatment options for patients in Europe with rare forms of cancer," said Sean E. Harper, M.D., executive vice president of Research and Development at Amgen. [More]
Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen, Xencor partner to develop and commercialize new therapeutics for cancer immunotherapy, inflammation

Amgen and Xencor, Inc. announced today that the two companies have entered into a research and license agreement to develop and commercialize novel therapeutics in the areas of cancer immunotherapy and inflammation. [More]
Advertisement
Advertisement